Arena Pharmaceuticals

-

Stock Issuer and Owners

Home | Sign Up | Log In
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
Latest Filings
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Arena Pharmaceuticals
TickerARNA
CIK #0001080709
CUSIP040047607
SectorLife Sciences
IndustryPharmaceutical Preparations
Phone8584537200
Address6166 Nancy Ridge Dr
San Diego, CA 92121
Source [EDGAR]
Market Cap, 13F ($MM)
19001520114076038002011201320152018
Business

We are a biopharmaceutical company focused on delivering novel, transformational medicines with optimized pharmacology and pharmacokinetics to patients globally. Our internally-developed pipeline includes multiple potentially first- or best-in-class assets with broad clinical utility.

Our most advanced investigational clinical programs include: etrasimod (APD334), being evaluated in a Phase 3 program for ulcerative colitis, or UC, a Phase 2b/3 program for Crohn's disease, or CD, and a Phase 2b program in atopic dermatitis, or AD. We also plan to evaluate etrasimod in a Phase 2b program for eosinophilic esophagitis, or EOE, and a Phase 2 program in alopecia areata, or AA. Olorinab (APD371) is being evaluated for a broad range of visceral pain conditions associated with gastrointestinal diseases and is currently in a Phase 2b trial for treatment of abdominal pain associated with irritable bowel syndrome, or IBS. APD418 is being evaluated in a Phase 1 trial for acute heart failure, or AHF.

We continue to leverage our two decades of world-class G-protein-coupled receptor, or GPCR, target discovery research to develop breakthrough drugs and ultimately deliver these to patients with large unmet needs. Our long-term pipeline prospects include an enhanced collaboration with Beacon Discovery across a broad range of immune-mediated inflammatory targets and compounds (which we refer to as Project Cabrillo) and the buildout of Arena Neuroscience to focus on treating neurological conditions with microglial neuroinflammation.

CIK Filing 2011 - 2021
[0001080709] 10-K
[0001080709] 10-Q
[0001080709] 3
[0001080709] 4
[0001080709] 5
[0001080709] 8-K
[0001080709] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Partner Fund Management LP Arena Pharmaceuticals Inc [2018-08-27] 5.1
FMR LLC Arena Pharmaceuticals Inc [2018-02-13] 0.0
Wellington Management Group LLP Arena Pharmaceuticals Inc [2018-02-08] 0.2
BlackRock Inc Arena Pharmaceuticals Inc [2018-01-29] 7.9
Great Point Partners LLC Arena Pharmaceuticals Inc [2017-04-28] 0.75
FMR LLC Arena Pharmaceuticals Inc [2016-02-12] 0.0
Vanguard Group Inc Arena Pharmaceuticals Inc [2013-02-13] 5.37
Form 3/4/5 Filer 2011-2021
Dallas Jayson Donald Alexander
Munshi Amit
Lisicki Robert
Cabell Christopher
Aurentz Vincent
Nova Tina Susan
SONI Manmeet Singh
Gallahue Kieran
Neil Garry Arthur
Jarrett Jennifer
Fetzer Oliver
Knobil Katharine
Stelzer Laurie
Schmidt Joan
LIND Kevin Robert
Klassen Preston
Spector Steven W
Woods Randall E
BICE Scott H
Schneider Phillip M
White Christine Anna
Hixson Harry F Jr
Belcher Donald D
Audet Craig Michael
Mezzino Maurice James
Bielasz Jennifer Kathleen
Shanahan William R Jr
Behan Dominic P
LIEF Jack
Hoffman Robert
MM Shares Owned of 49.3 MM Total
Firm Period DFND Voting Shares
BlackRock Inc. [2020-09-30] SOLE 5.2 5.3
Vanguard Group Inc [2020-09-30] SOLE 0.0 5.0
Wellington Management Co LLP [2020-09-30] DFND 0.0 4.2
venBio Select Advisor LLC [2020-09-30] SOLE 3.1 3.1
Lord Abbett & Co LLC [2020-09-30] SOLE 2.0 2.0
State Street Corp [2020-09-30] DFND 1.7 1.9
Alkeon Capital Management LLC [2020-09-30] SOLE 1.4 1.4
Point72 Asset Management LP [2020-09-30] DFND 0.0 1.3
AllianceBernstein LP [2020-09-30] DFND 0.9 1.0
Great Point Partners LLC [2020-09-30] DFND 1.0 1.0
Marshall Wace North America LP [2020-09-30] OTR 0.0 1.0
Northern Trust Corp [2020-09-30] DFND 0.2 1.0
Holocene Advisors LP [2020-09-30] SOLE 1.0 1.0
Goldman Sachs Group Inc [2020-09-30] DFND 0.9 0.9
Pictet Asset Management Ltd [2020-09-30] DFND 0.0 0.9
HealthCor Management LP [2020-09-30] SOLE 0.9 0.9
Geode Capital Management LLC [2020-09-30] DFND 0.9 0.9
FMR LLC [2020-09-30] DFND 0.0 0.8
Bank of New York Mellon Corp [2020-09-30] DFND 0.7 0.8
Dimensional Fund Advisors LP [2020-09-30] DFND 0.7 0.7
Gilder Gagnon Howe & Co LLC [2020-09-30] DFND 0.0 0.6
Farallon Capital Management LLC [2020-09-30] OTR 0.6 0.6
Perceptive Advisors LLC [2020-09-30] SOLE 0.6 0.6
Nuveen Asset Management LLC [2020-09-30] DFND 0.6 0.6
Credit Suisse AG [2020-09-30] DFND 0.6 0.6
Eagle Asset Management Inc [2020-09-30] SOLE 0.6 0.6
PRIMECAP Management Co/Ca/ [2020-09-30] SOLE 0.5 0.5
Macquarie Group Ltd [2020-09-30] SOLE 0.5 0.5
Victory Capital Management Inc [2020-09-30] SOLE 0.5 0.5
Wells Fargo & Co/Mn [2020-09-30] DFND 0.1 0.4
Prev | Page 1 | Next
Terms | Privacy | Guide
tony@aum13f.com